MCF Advisors’s Royalty Pharma RPRX Stock Holding History

MCF Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-340	Closed	-$9.62K	–	1037
2024 Q3	$9.62K	Hold	340	–	–	﹤0.01%	654
2024 Q2	$8.97K	Hold	340	–	–	﹤0.01%	664
2024 Q1	$10.3K	Buy	+340	New	+$10K	﹤0.01%	623

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MCF Advisors's RPRX Position: Q4 2024 in Review

MCF Advisors sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 340 shares — an estimated $9.62K sold.

MCF Advisors first reported a position in RPRX in Q1 2024 and held it in 3 quarters. The position peaked at $10.3K in Q1 2024. 417 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

MCF Advisors reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
MCF Advisors sold 340 Royalty Pharma shares in Q4 2024, an estimated $9.62K.
MCF Advisors first reported a position in Royalty Pharma in Q1 2024 and held it in 3 quarters.
MCF Advisors's Royalty Pharma position peaked at $10.3K in Q1 2024.
417 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on MCF Advisors's 13F filing for Q4 2024, filed 17 Jan 2025.